| Budget Amount *help |
¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
Fiscal Year 2019: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2018: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Outline of Final Research Achievements |
Eleven patients with head and neck cancer underwent both MET and FDG PET/CT before treatment. Each tracer uptake in the primary tumor was evaluated. All 11 primary cancers were visualized by both tracers. The MET SUVmax, MTV, and the total lesion methionine uptake (TLMU) values were 12.2±5.8, 7.2±8.5, and 69±113.1, respectively. The FDG SUVmax, MTV, and the total lesion glycolysis (TLG) values were 12.6±9.1, 5.9±7.3, and 73.2±127.3, respectively. The difference between MET and FDG was not significant with any uptake parameter (12.2±5.8 and 12.6±9.1, p=0.863 for SUVmax; 7.2±8.5 and 5.9±7.3, p=0.139 for MTV; 69±113.1 and 73.2±127.3, p=0.075 for TLMU, TLG). The MET SUVmax, MTV, and TLMU demonstrated a significantly positive, strong correlation with the FDG SUVmax, MTV, and TLG, respectively (r=0.725 [p=0.012], r=0.881 [p<0.001], r=0.955 [p<0.001]). MET has the same utility as FDG in PET/CT for the visualization of primary head and neck cancer.
|
